Depression and Anxiety Scores Are Associated with Amygdala Volume in Cushing’s Syndrome: Preliminary Study

Table 1

Clinical characteristics of patients with Cushing’s syndrome (CS) and controls.

	CS ()		Controls; ()
	Active; ()	In remission; ()
Age	44.1 ± 9.0	42.9 ± 10.6	42.6 ± 10.3
Sex (female/male)	14/2	19/4	33/6
Years of education	13.9 ± 2.7	13.2 ± 3.3	13.9 ± 3.3
Origin of CS (pituitary/adrenal/ectopic/AIMAH^†)	10/4/1/1	20/3/0/0	—
Cortisol lowering medication (Metyrapone/Ketoconazole/Cabergoline/Losartan)	4/8/1/1	—	—
Mean length of treatment with cortisol lowering medication (months)	4.4 ± 4.	—	—
Hydrocortisone replacement	—	8	—
Antidepressive medication	1	5	—
Recurrencies	1	3	—
Radiotherapy	—	5	—
Mean duration of hypercortisolism (months)	62.2 ± 59.1	63.1 ± 34.6	—
Delay to diagnosis (months)	49.1 ± 42.7	44.4 ± 36.1	—
Mean time of biochemical cure (months)	—	66.0 ± 69.0	—
Urinary free cortisol (nmol/24 h)	350.4 ± 293.1	124.8 ± 49.2	145.5 ± 88.9

the whole sample of patients taking cortisol-lowering medication except one patient with an ectopic ACTH secretion who had been taking medication for 120 months.
: ACTH-independent macronodular adrenal hyperplasia.